<?xml version="1.0" encoding="UTF-8"?>
<p>The administration of PCS to Alloxan-induced diabetic mice significantly (
 <italic>p</italic> &lt; 0.001) reduced the level of LDL by 61% and 46% (25 and 50 b.w., respectively). At the same time, the glibenclamide group marked an increase in LDL level by 31% compared to normal control along with the diabetic control group, which has the most improvement with +77% compared to the normal control. As for The HDL level compared to normal control, all groups exhibited a decrease with −33% for diabetic control −12% noted for glibenclamide, and −20% for the groups treated with both doses of PCS. 
</p>
